Mr. Christopher Moreau reports

GREY MATTERS ANNOUNCES SEPTEMBER OPENING OF ITS FIRST BRAIN DEDICATED PET NEUROIMAGING CLINIC IN THE U.S.

Grey Matters Health Inc. plans to open its flagship NovaScan Neuroimaging Clinics location next month in Davie, Fla., and conduct a brain PET (positron emission tomography) scan of its first patient by Sept. 30, 2026.

"We are very pleased to announce the timeline of our planned opening," said Christopher J. Moreau, chief executive officer of Grey Matters Health. "Our team is working diligently to prepare for the launch of our flagship clinic featuring new U.S. FDA-cleared brain imaging technology and an elevated, patient-focused approach to clinical services and care."

The inaugural NovaScan Neuroimaging Clinics location is at the HCA Florida University Medical Office Building in Davie, located on the campus of the HCA Florida University Hospital, and will be the first of its kind in the United States to provide brain dedicated PET scans to aid in the detection of Alzheimer's disease (AD) and other forms of neurodegenerative diseases, including frontotemporal dementia, Parkinson's and Lewy body dementia, and will be additionally used for other select neuro-oncology applications.

Brain PET scans for beta-amyloid plaque detection (associated with advancing AD) are covered by Medicare, Medicaid and private insurance for those over 65, with patients being referred to NovaScan Neuroimaging Clinics by neurologists, geriatricians and primary care physicians. The clinic will feature the U.S. FDA-cleared (U.S. Food and Drug Administration) CareMiBrain system, a groundbreaking, new seated diagnostic brain PET scanner that does not need an integrated computed tomography (CT) component to produce high-quality images, resulting in 25 per cent less radiation exposure for patients.

There are two recently U.S. FDA-approved monoclonal antibody treatments for AD, which are also covered by Medicare, Medicaid and private insurance, designed to slow the progression of the disease -- Leqembi (Eisai and Biogen) and Kisunla (Eli Lilly) -- and both require a positive beta-amyloid brain scan (or spinal tap) in order for patients to be authorized to receive them. These drugs can dissolve amyloid plaque buildup in the brain and slow the progression of a patient's cognitive decline and have helped create a billion-dollar market opportunity for the brain-specific PET scan and AD treatment space.

The United States' current supply of PET scanners -- the majority being a PET/CT hybrid technology -- is vastly insufficient to serve the massive new market emerging for AD diagnostics and treatment. The majority of PET/CT scanners, 45 per cent of which are located in hospitals, are primarily prioritized as cancer diagnostic and theranostic tools and for cardiac imaging, which can make it challenging to schedule brain-specific scans on a timely basis.

The Grey Matters Health business plan is to open a national chain of its NovaScan Neuroimaging Clinics throughout the United States.

About Grey Matters Health Inc.

Grey Matters is a Canadian health care company focused on the provision of brain-dedicated PET scanning services through a planned network of new neuroimaging clinics in the United States for the early-stage detection of Alzheimer's disease and other forms of neurodegenerative diseases, including frontotemporal dementia, Parkinson's and Lewy body dementia, and will additionally offer other select neuro-oncology imaging applications.

We seek Safe Harbor.